Effects of monotherapy with (R)-9-(2-phosphonylmethoxypropyl)adenine (PMPA) on the evolution of a primary Simian immunodeficiency virus (SIV) isolate

Virology

Volumn 354, Issue 1, 2006, Pages 116-131

  Taber, Rachel ^a   Rajakumar, Premeela A ^a   Fuller, Deborah Heydenburg ^a   Trichel, Anita M ^a   Dowling, Patricia ^a   Meleason, David ^a   Amedee, Angela ^b   Murphey Corb, Michael ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

(R) 9 (2 phosphonylmethoxypropyl) adenine (PMPA); Antiretroviral therapy (ART); Diversity; Envelope; Evolution; Heteroduplex tracking analysis (HTA); SIV

Indexed keywords

TENOFOVIR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG RESPONSE; DRUG WITHDRAWAL; EVOLUTION; GENOTYPE; IN VITRO STUDY; MACACA; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE; VIRUS INFECTION; VIRUS ISOLATION; VIRUS LOAD;

ADENINE; AMINO ACID SEQUENCE; ANIMALS; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; EVOLUTION, MOLECULAR; GENOME, VIRAL; GENOTYPE; GLYCOSYLATION; HETERODUPLEX ANALYSIS; HUMANS; MACACA MULATTA; MOLECULAR SEQUENCE DATA; PHOSPHONIC ACIDS; SEQUENCE HOMOLOGY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; T-LYMPHOCYTES; VIRAL LOAD; VIRUS REPLICATION;

ANIMALIA; MACACA MULATTA; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 33749122056     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2006.06.025     Document Type: Article

References (66)

1. Albert J., Abrahamsson B., Nagy K., Aurelius E., Gaines H., Nystrom G., and Fenyo E.M. Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. AIDS 4 2 (1990) 107-112
2. Allen T.M., Sidney J., del Guercio M.F., Glickman R.L., Lensmeyer G.L., Wiebe D.A., DeMars R., Pauza C.D., Johnson R.P., Sette A., and Watkins D.I. Characterization of the peptide binding motif of a rhesus MHC class I molecule (Mamu-A*01) that binds an immunodominant CTL epitope from simian immunodeficiency virus. J. Immunol. 160 12 (1998) 6062-6071
3. Allen T.M., O'Connor D.H., Jing P., Dzuris J.L., Mothe B.R., Vogel T.U., Dunphy E., Liebl M.E., Emerson C., Wilson N., Kunstman K.J., Wang X., Allison D.B., Hughes A.L., Desrosiers R.C., Altman J.D., Wolinsky S.M., Sette A., and Watkins D.I. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature 407 6802 (2000) 386-390
4. Allen T.M., Mothe B.R., Sidney J., Jing P., Dzuris J.L., Liebl M.E., Vogel T.U., O'Connor D.H., Wang X., Wussow M.C., Thomson J.A., Altman J.D., Watkins D.I., and Sette A. CD8 (+) lymphocytes from simian immunodeficiency virus-infected rhesus macaques recognize 14 different epitopes bound by the major histocompatibility complex class I molecule mamu-A*01: implications for vaccine design and testing. J. Virol. 75 2 (2001) 738-749
5. Allen T.M., Altfeld M., Geer S.C., Kalife E.T., Moore C., O'Sullivan K M., Desouza I., Feeney M.E., Eldridge R.L., Maier E.L., Kaufmann D.E., Lahaie M.P., Reyor L., Tanzi G., Johnston M.N., Brander C., Draenert R., Rockstroh J.K., Jessen H., Rosenberg E.S., Mallal S.A., and Walker B.D. Selective escape from CD8+ T-cell responses represents a major driving force of human immunodeficiency virus type 1 (HIV-1) sequence diversity and reveals constraints on HIV-1 evolution. J. Virol. 79 21 (2005) 13239-13249
6. Amedee A.M., Lacour N., Gierman J.L., Martin L.N., Clements J.E., Bohm Jr. R., Harrison R.M., and Murphey-Corb M. Genotypic selection of simian immunodeficiency virus in macaque infants infected transplacentally. J. Virol. 69 12 (1995) 7982-7990
7. Bagnarelli P., Menzo S., Valenza A., Paolucci S., Petroni S., Scalise G., Sampaolesi R., Manzin A., Varaldo P.E., and Clementi M. Quantitative molecular monitoring of human immunodeficiency virus type 1 activity during therapy with specific antiretroviral compounds. J. Clin. Microbiol. 33 1 (1995) 16-23
8. Borrow P., Lewicki H., Wei X., Horwitz M.S., Peffer N., Meyers H., Nelson J.A., Gairin J.E., Hahn B.H., Oldstone M.B., and Shaw G.M. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat. Med. 3 2 (1997) 205-211
9. Buckheit Jr. R.W. Understanding HIV resistance, fitness, replication capacity and compensation: targeting viral fitness as a therapeutic strategy. Expert Opin. Invest. Drugs 13 8 (2004) 933-958
10. Chackerian B., Rudensey L.M., and Overbaugh J. Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies. J. Virol. 71 10 (1997) 7719-7727
11. Chen Z.W., Craiu A., Shen L., Kuroda M.J., Iroku U.C., Watkins D.I., Voss G., and Letvin N.L. Simian immunodeficiency virus evades a dominant epitope-specific cytotoxic T lymphocyte response through a mutation resulting in the accelerated dissociation of viral peptide and MHC class I. J. Immunol. 164 12 (2000) 6474-6479
12. Chun T.W., Carruth L., Finzi D., Shen X., DiGiuseppe J.A., Taylor H., Hermankova M., Chadwick K., Margolick J., Quinn T.C., Kuo Y.H., Brookmeyer R., Zeiger M.A., Barditch-Crovo P., and Siliciano R.F. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387 6629 (1997) 183-188
13. Chun T.W., Davey Jr. R.T., Ostrowski M., Shawn Justement J., Engel D., Mullins J.I., and Fauci A.S. Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy. Nat. Med. 6 7 (2000) 757-761
14. Condra J.H., Schleif W.A., Blahy O.M., Gabryelski L.J., Graham D.J., Quintero J.C., Rhodes A., Robbins H.L., Roth E., Shivaprakash M., et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374 6522 (1995) 569-571
15. Courgnaud V., Saurin W., Villinger F., and Sonigo P. Different evolution of simian immunodeficiency virus in a natural host and a new host. Virology 247 1 (1998) 41-50
16. Delwart E.L., and Gordon C.J. Tracking changes in HIV-1 envelope quasispecies using DNA heteroduplex analysis. Methods 12 4 (1997) 348-354
17. Delwart E.L., Shpaer E.G., Louwagie J., McCutchan F.E., Grez M., Rubsamen-Waigmann H., and Mullins J.I. Genetic relationships determined by a DNA heteroduplex mobility assay: analysis of HIV-1 env genes. Science 262 5137 (1993) 1257-1261
18. Delwart E.L., Busch M.P., Kalish M.L., Mosley J.W., and Mullins J.I. Rapid molecular epidemiology of human immunodeficiency virus transmission. AIDS Res. Hum. Retrovir. 11 9 (1995) 1081-1093
19. Demma L.J., Logsdon J.M., Vanderford T.H., Feinberg M.B., and Staprans S.I. SIVsm quasispecies adaptation to a new simian host. PLoS Pathog. 1 1 (2005) e3
20. Detels R., Munoz A., McFarlane G., Kingsley L.A., Margolick J.B., Giorgi J., Schrager L.K., and Phair J.P. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA 280 17 (1998) 1497-1503
21. Devereux H.L., Youle M., Johnson M.A., and Loveday C. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS 13 18 (1999) F123-F127
22. Devereux H.L., Emery V.C., Johnson M.A., and Loveday C. Replicative fitness in vivo of HIV-1 variants with multiple drug resistance-associated mutations. J. Med. Virol. 65 2 (2001) 218-224
23. Dybul M., Daucher M., Jensen M.A., Hallahan C.W., Chun T.W., Belson M., Hidalgo B., Nickle D.C., Yoder C., Metcalf J.A., Davey R.T., Ehler L., Kress-Rock D., Nies-Kraske E., Liu S., Mullins J.I., and Fauci A.S. Genetic characterization of rebounding human immunodeficiency virus type 1 in plasma during multiple interruptions of highly active antiretroviral therapy. J. Virol. 77 5 (2003) 3229-3237
24. Egger M., Hirschel B., Francioli P., Sudre P., Wirz M., Flepp M., Rickenbach M., Malinverni R., Vernazza P., and Battegay M. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. Bmj 315 7117 (1997) 1194-1199
25. Evans D.T., O'Connor D.H., Jing P., Dzuris J.L., Sidney J., da Silva J., Allen T.M., Horton H., Venham J.E., Rudersdorf R.A., Vogel T., Pauza C.D., Bontrop R.E., DeMars R., Sette A., Hughes A.L., and Watkins D.I. Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef. Nat. Med. 5 11 (1999) 1270-1276
26. Fuller D.H., Rajakumar P.A., Wilson L.A., Trichel A.M., Fuller J.T., Shipley T., Wu M.S., Weis K., Rinaldo C.R., Haynes J.R., and Murphey-Corb M. Induction of mucosal protection against primary, heterologous simian immunodeficiency virus by a DNA vaccine. J. Virol. 76 7 (2002) 3309-3317
27. Fuller D.H., Rajakumar P.A., Wu M.S., McMahon C.W., Shipley T., Fuller J.T., Bazmi A., Trichel A.M., Allen T.M., Mothe B., Haynes J.R., Watkins D.I., and Murphey-Corb M. DNA immunization in combination with effective antiretroviral drug therapy controls viral rebound and prevents simian AIDS after treatment is discontinued. Virology 348 (2006) 200-215
28. George M.D., Reay E., Sankaran S., and Dandekar S. Early antiretroviral therapy for simian immunodeficiency virus infection leads to mucosal CD4+ T-cell restoration and enhanced gene expression regulating mucosal repair and regeneration. J. Virol. 79 5 (2005) 2709-2719
29. Goulder P.J., Phillips R.E., Colbert R.A., McAdam S., Ogg G., Nowak M.A., Giangrande P., Luzzi G., Morgan B., Edwards A., McMichael A.J., and Rowland-Jones S. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat. Med. 3 2 (1997) 212-217
30. Grabar S., Le Moing V., Goujard C., Leport C., Kazatchkine M.D., Costagliola D., and Weiss L. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann. Intern. Med. 133 6 (2000) 401-410
31. Greenier J.L., Van Rompay K.K., Montefiori D., Earl P., Moss B., and Marthas M.L. Simian immunodeficiency virus (SIV) envelope quasispecies transmission and evolution in infant rhesus macaques after oral challenge with uncloned SIVmac251: increased diversity is associated with neutralizing antibodies and improved survival in previously immunized animals. Virol. J. 2 (2005) 11
32. Hansen J.E., Lund O., Tolstrup N., Gooley A.A., Williams K.L., and Brunak S. NetOglyc: prediction of mucin type O-glycosylation sites based on sequence context and surface accessibility. Glycoconjugate. J. 15 2 (1998) 115-130
33. Hel Z., Venzon D., Poudyal M., Tsai W.P., Giuliani L., Woodward R., Chougnet C., Shearer G., Altman J.D., Watkins D., Bischofberger N., Abimiku A., Markham P., Tartaglia J., and Franchini G. Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques. Nat. Med. 6 10 (2000) 1140-1146
34. Holterman L., Dubbes R., Mullins J., Learn G., Niphuis H., Koornstra W., Koopman G., Kuhn E.M., Wade-Evans A., Rosenwirth B., Haaijman J., and Heeney J. Characteristics of a pathogenic molecular clone of an end-stage serum-derived variant of simian immunodeficiency virus (SIV (F359)). J. Virol. 75 19 (2001) 9328-9338
35. Joos B., Trkola A., Fischer M., Kuster H., Rusert P., Leemann C., Boni J., Oxenius A., Price D.A., Phillips R.E., Wong J.K., Hirschel B., Weber R., and Gunthard H.F. Low human immunodeficiency virus envelope diversity correlates with low in vitro replication capacity and predicts spontaneous control of plasma viremia after treatment interruptions. J. Virol. 79 14 (2005) 9026-9037
36. Kaufmann D., Pantaleo G., Sudre P., and Telenti A. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study. Lancet 351 9104 (1998) 723-724
37. Kijak G.H., Simon V., Balfe P., Vanderhoeven J., Pampuro S.E., Zala C., Ochoa C., Cahn P., Markowitz M., and Salomon H. Origin of human immunodeficiency virus type 1 quasispecies emerging after antiretroviral treatment interruption in patients with therapeutic failure. J. Virol. 76 14 (2002) 7000-7009
38. Kimata J.T., Kuller L., Anderson D.B., Dailey P., and Overbaugh J. Emerging cytopathic and antigenic simian immunodeficiency virus variants influence AIDS progression. Nat. Med. 5 5 (1999) 535-541
39. Knapp L.A., Lehmann E., Piekarczyk M.S., Urvater J.A., and Watkins D.I. A high frequency of Mamu-A*01 in the rhesus macaque detected by polymerase chain reaction with sequence-specific primers and direct sequencing. Tissue Antigens 50 6 (1997) 657-661
40. Koch M., Pancera M., Kwong P.D., Kolchinsky P., Grundner C., Wang L., Hendrickson W.A., Sodroski J., and Wyatt R. Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition. Virology 313 2 (2003) 387-400
41. Lifson J.D., Rossio J.L., Arnaout R., Li L., Parks T.L., Schneider D.K., Kiser R.F., Coalter V.J., Walsh G., Imming R.J., Fisher B., Flynn B.M., Bischofberger N., Piatak Jr. M., Hirsch V.M., Nowak M.A., and Wodarz D. Containment of simian immunodeficiency virus infection: cellular immune responses and protection from rechallenge following transient postinoculation antiretroviral treatment. J. Virol. 74 6 (2000) 2584-2593
42. Lukashov V.V., Kuiken C.L., and Goudsmit J. Intrahost human immunodeficiency virus type 1 evolution is related to length of the immunocompetent period. J. Virol. 69 11 (1995) 6911-6916
43. Magierowska M., Bernardin F., Garg S., Staprans S., Miller M.D., Van Rompay K.K., and Delwart E.L. Highly uneven distribution of tenofovir-selected simian immunodeficiency virus in different anatomical sites of rhesus macaques. J. Virol. 78 5 (2004) 2434-2444
44. Martin L.N., Murphey-Corb M., Soike K.F., Davison-Fairburn B., and Baskin G.B. Effects of initiation of 3′-azido,3′-deoxythymidine (zidovudine) treatment at different times after infection of rhesus monkeys with simian immunodeficiency virus. J. Infect. Dis. 168 4 (1993) 825-835
45. Mellors J.W., Rinaldo Jr. C.R., Gupta P., White R.M., Todd J.A., and Kingsley L.A. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272 5265 (1996) 1167-1170
46. Montefiori D.C., Zhou I.Y., Barnes B., Lake D., Hersh E.M., Masuho Y., and Lefkowitz Jr. L.B. Homotypic antibody responses to fresh clinical isolates of human immunodeficiency virus. Virology 182 2 (1991) 635-643
47. Mothe B.R., Weinfurter J., Wang C., Rehrauer W., Wilson N., Allen T.M., Allison D.B., and Watkins D.I. Expression of the major histocompatibility complex class I molecule Mamu-A*01 is associated with control of simian immunodeficiency virus SIVmac239 replication. J. Virol. 77 4 (2003) 2736-2740
48. Murphey-Corb M., Martin L.N., Rangan S.R., Baskin G.B., Gormus B.J., Wolf R.H., Andes W.A., West M., and Montelaro R.C. Isolation of an HTLV-III-related retrovirus from macaques with simian AIDS and its possible origin in asymptomatic mangabeys. Nature 321 6068 (1986) 435-437
49. O'Connor D.H., McDermott A.B., Krebs K.C., Dodds E.J., Miller J.E., Gonzalez E.J., Jacoby T.J., Yant L., Piontkivska H., Pantophlet R., Burton D.R., Rehrauer W.M., Wilson N., Hughes A.L., and Watkins D.I. A dominant role for CD8+-T-lymphocyte selection in simian immunodeficiency virus sequence variation. J. Virol. 78 24 (2004) 14012-14022
50. Overbaugh J., Rudensey L.M., Papenhausen M.D., Benveniste R.E., and Morton W.R. Variation in simian immunodeficiency virus env is confined to V1 and V4 during progression to simian AIDS. J. Virol. 65 12 (1991) 7025-7031
51. Pal R., Venzon D., Letvin N.L., Santra S., Montefiori D.C., Miller N.R., Tryniszewska E., Lewis M.G., VanCott T.C., Hirsch V., Woodward R., Gibson A., Grace M., Dobratz E., Markham P.D., Hel Z., Nacsa J., Klein M., Tartaglia J., and Franchini G. ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency. J. Virol. 76 1 (2002) 292-302
52. Palella Jr. F.J., Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., Satten G.A., Aschman D.J., and Holmberg S.D. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med. 338 13 (1998) 853-860
53. Price D.A., Goulder P.J., Klenerman P., Sewell A.K., Easterbrook P.J., Troop M., Bangham C.R., and Phillips R.E. Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. Proc. Natl. Acad. Sci. U.S.A. 94 5 (1997) 1890-1895
54. Rybarczyk B.J., Montefiori D., Johnson P.R., West A., Johnston R.E., and Swanstrom R. Correlation between env V1/V2 region diversification and neutralizing antibodies during primary infection by simian immunodeficiency virus sm in rhesus macaques. J. Virol. 78 7 (2004) 3561-3571
55. Rychert J., Lacour N., and Amedee A.M. Genetic analysis of simian immunodeficiency virus expressed in milk and selectively transmitted through breastfeeding. J. Virol. 80 8 (2006) 3721-3731
56. Shankarappa R., Margolick J.B., Gange S.J., Rodrigo A.G., Upchurch D., Farzadegan H., Gupta P., Rinaldo C.R., Learn G.H., He X., Huang X.L., and Mullins J.I. Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J. Virol. 73 12 (1999) 10489-10502
57. Staprans S.I., Dailey P.J., Rosenthal A., Horton C., Grant R.M., Lerche N., and Feinberg M.B. Simian immunodeficiency virus disease course is predicted by the extent of virus replication during primary infection. J. Virol. 73 6 (1999) 4829-4839
58. Thompson J.D., Gibson T.J., Plewniak F., Jeanmougin F., and Higgins D.G. The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res. 25 24 (1997) 4876-4882
59. Trichel A.M., Roberts E.D., Wilson L.A., Martin L.N., Ruprecht R.M., and Murphey-Corb M. SIV/DeltaB670 transmission across oral, colonic, and vaginal mucosae in the macaque. J. Med. Primatol. 26 1-2 (1997) 3-10
60. Trichel A.M., Rajakumar P.A., and Murphey-Corb M. Species-specific variation in SIV disease progression between Chinese and Indian subspecies of rhesus macaque. J. Med. Primatol. 31 4-5 (2002) 171-178
61. Van Rompay K.K., Cherrington J.M., Marthas M.L., Berardi C.J., Mulato A.S., Spinner A., Tarara R.P., Canfield D.R., Telm S., Bischofberger N., and Pedersen N.C. 9-[2-(Phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques. Antimicrob. Agents Chemother. 40 11 (1996) 2586-2591
62. Van Rompay K.K., Singh R.P., Pahar B., Sodora D.L., Wingfield C., Lawson J.R., Marthas M.L., and Bischofberger N. CD8+-cell-mediated suppression of virulent simian immunodeficiency virus during tenofovir treatment. J. Virol. 78 10 (2004) 5324-5337
63. Watson A., Ranchalis J., Travis B., McClure J., Sutton W., Johnson P.R., Hu S.L., and Haigwood N.L. Plasma viremia in macaques infected with simian immunodeficiency virus: plasma viral load early in infection predicts survival. J. Virol. 71 1 (1997) 284-290
64. Wei X., Decker J.M., Wang S., Hui H., Kappes J.C., Wu X., Salazar-Gonzalez J.F., Salazar M.G., Kilby J.M., Saag M.S., Komarova N.L., Nowak M.A., Hahn B.H., Kwong P.D., and Shaw G.M. Antibody neutralization and escape by HIV-1. Nature 422 6929 (2003) 307-312
65. Zhang J.Y., Martin L.N., Watson E.A., Montelaro R.C., West M., Epstein L., and Murphey-Corb M. Simian immunodeficiency virus/delta-induced immunodeficiency disease in rhesus monkeys: relation of antibody response and antigenemia. J. Infect. Dis. 158 6 (1988) 1277-1286
66. Zhang L., Chung C., Hu B.S., He T., Guo Y., Kim A.J., Skulsky E., Jin X., Hurley A., Ramratnam B., Markowitz M., and Ho D.D. Genetic characterization of rebounding HIV-1 after cessation of highly active antiretroviral therapy. J. Clin. Invest. 106 7 (2000) 839-845